| Literature DB >> 30496310 |
Lattha Souvannaseng1,2, Lewis Vibul Hun3, Heather Baker1, John M Klyver1, Bo Wang1, Nazzy Pakpour1, Jordan M Bridgewater3, Eleonora Napoli4, Cecilia Giulivi4,5, Michael A Riehle3, Shirley Luckhart6.
Abstract
Malaria is a global health concern caused by infection with Plasmodium parasites. With rising insecticide and drug resistance, there is a critical need to develop novel control strategies, including strategies to block parasite sporogony in key mosquito vector species. MAPK signaling pathways regulated by extracellular signal-regulated kinases (ERKs) and the stress-activated protein kinases (SAPKs) c-Jun N-terminal kinases (JNKs) and p38 MAPKs are highly conserved across eukaryotes, including mosquito vectors of the human malaria parasite Plasmodium falciparum. Some of these pathways in mosquitoes have been investigated in detail, but the mechanisms of integration of parasite development and mosquito fitness by JNK signaling have not been elucidated. To this end, we engineered midgut-specific overexpression of MAPK phosphatase 4 (MKP4), which targets the SAPKs, and used two potent and specific JNK small molecule inhibitors (SMIs) to assess the effects of JNK signaling manipulations on Anopheles stephensi fecundity, lifespan, intermediary metabolism, and P. falciparum development. MKP4 overexpression and SMI treatment reduced the proportion of P. falciparum-infected mosquitoes and decreased oocyst loads relative to controls. SMI-treated mosquitoes exhibited no difference in lifespan compared to controls, whereas genetically manipulated mosquitoes exhibited extended longevity. Metabolomics analyses of SMI-treated mosquitoes revealed insights into putative resistance mechanisms and the physiology behind lifespan extension, suggesting for the first time that P. falciparum-induced JNK signaling reduces mosquito longevity and increases susceptibility to infection, in contrast to previously published reports, likely via a critical interplay between the invertebrate host and parasite for nutrients that play essential roles during sporogonic development.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30496310 PMCID: PMC6264519 DOI: 10.1371/journal.ppat.1007418
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Fig 15Midgut permeability was inconsistently altered by treatment with JNK SMIs and unaffected by midgut MKP4 overexpression.
Non-transgenic (control) A. stephensi (3–5 day old) were fed on artificial blood meals containing 2.0–2.4 μm magnetic fluorescent particles (Spherotech) with or without supplementation with 1 μM JNK-IN-8 or 1 μM TCS JNK 6o. Particle numbers were quantified at 72 h post-blood feeding as described in the methods. Dots represent particle numbers per five mosquitoes and bars indicate the means. Data were analyzed by one-way ANOVA.
List of vertebrate, fly, and mosquito MKP genes.
| Vertebrate | ||||||||
|---|---|---|---|---|---|---|---|---|
| Gene | Synonym | Gene | Gene | Protein | Gene | Protein | ||
| MKP-1 | ||||||||
| PAC-2 | ||||||||
| MKP-2 | ||||||||
| hVH3/B23 | ||||||||
| MKP-3 | MKP3 | AGAP012237 | AgMKP3 | ASTE011534 | AsMKP3 | |||
| PYST2 | ||||||||
| MKP-4 | ||||||||
| hVH5 | ||||||||
| MKP-5 | puckered | AGAP004353 | AgMKP5 | ASTE002907 | AsMKP5 | |||
| MKP-7 | ||||||||
| VHX | MKP4 | AGAP002108 | AgMKP4 | ASTE004228 | AsMKP4 | |||
| BEDPA | CG7378 | AGAP008228 | — | ASTE005078 | — | |||
| MKP-6 | CG15528 | AGAP006593 | — | ASTE007826 | — | |||
| SKRP1 | MKP | AGAP009903 | AgMKP | ASTE009886 | AsMKP | |||
*Homo sapiens and Mus musculus
Analysis of replicate lifespan studies of A. stephensi provided weekly blood meals with JNK-IN-8 or TCS JNK 6o relative to controls.
| Replicate | Log-Rank Mantel Cox | Significantly different? | Gehan-Breslow-Wilcoxon | Significantly different? | |
|---|---|---|---|---|---|
| 1 | Ctrl vs. IN8 | 0.0002 | Y | 0.0005 | Y |
| Ctrl vs. 6o | 0.0060 | Y | 0.0066 | Y | |
| 2 | Ctrl vs. IN8 | 0.2258 | N | 0.918 | N |
| Ctrl vs. 6o | 0.2920 | N | 0.7092 | N | |
| 3 | Ctrl vs. IN8 | 0.2557 | N | 0.4146 | N |
| Ctrl vs. 6o | 0.0840 | N | 0.5354 | N | |
| 4 | Ctrl vs. IN8 | 0.6492 | N | 0.9208 | N |
| Ctrl vs. 6o | 0.7425 | N | 0.8301 | N | |
| 5 | Ctrl vs. IN8 | 0.8337 | N | 0.7483 | N |
| Ctrl vs. 6o | 0.0132 | Y | 0.0217 | Y | |
| 6 | Ctrl vs. IN8 | 0.8936 | N | 0.6031 | N |
| Ctrl vs. 6o | 0.7193 | N | 0.4041 | N | |
| 7 | Ctrl vs. IN8 | 0.0038 | Y | 0.1094 | N |
| Ctrl vs. 6o | 0.9906 | N | 0.5927 | N | |
| 8 | Ctrl vs. IN8 | <0.0001 | Y | <0.0001 | Y |
| Ctrl vs. 6o | 0.0408 | Y | 0.221 | N | |
| 9 | Ctrl vs. IN8 | 0.9591 | N | 0.6036 | N |
| Ctrl vs. 6o | 0.1263 | N | 0.2406 | N | |
| 10 | Ctrl vs. IN8 | 0.0042 | Y | 0.0226 | Y |
| Ctrl vs. 6o | 0.0644 | N | 0.0566 | N | |
| 11 | Ctrl vs. IN8 | 0.0967 | N | 0.9709 | N |
| Ctrl vs. 6o | 0.0204 | Y | 0.1332 | N |
Moderate inhibition of JNK reduces P. falciparum oocyst development in A. stephensi.
| Control | JNK-IN-8 | TCS JNK 6o | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Exp | N | mean oocyst±SEM | % inf | N | mean oocyst±SEM | % inf | p-value | N | mean oocyst±SEM | % inf | p-value |
| 1 | 42 | 0.71±0.13 | 52.4 | 38 | 0.34±0.12 | 21.1 | 0.0097 | 38 | 0.39±0.12 | 36.3 | 0.0366 |
| 2 | 38 | 1.11±0.20 | 57.9 | 42 | 0.43±0.10 | 35.7 | 0.0114 | 41 | 0.56±0.13 | 39.0 | 0.0574 |
| 3 | 46 | 1.20±0.18 | 67.4 | 41 | 0.54±0.14 | 31.7 | 0.0032 | 44 | 0.73±0.15 | 45.5 | 0.0666 |
List of the pathways identified and their relative impacts.
| Pathway | Total Compounds | Hits | Raw p | LN p | Holm adjust | FDR | Impact |
|---|---|---|---|---|---|---|---|
| Steroid biosynthesis | 4 | 1 | 0.005 | 5.39 | 0.21942 | 0.096 | 0.000 |
| Linoleic acid metabolism | 6 | 1 | 0.006 | 5.14 | 0.27666 | 0.096 | 1.000 |
| Pentose and glucuronate interconversions | 14 | 2 | 0.006 | 5.12 | 0.27666 | 0.096 | 0.364 |
| Inositol phosphate metabolism | 24 | 2 | 0.064 | 2.74 | 1 | 0.385 | 0.204 |
| Synthesis and degradation of ketone bodies | 5 | 1 | 0.069 | 2.68 | 1 | 0.385 | 0.000 |
| Trp metabolism | 23 | 1 | 0.077 | 2.57 | 1 | 0.385 | 0.000 |
| beta‐Ala metabolism | 13 | 6 | 0.089 | 2.42 | 1 | 0.385 | 0.483 |
| Glycerophospholipid metabolism | 27 | 2 | 0.094 | 2.36 | 1 | 0.385 | 0.033 |
| Glutathione metabolism | 26 | 6 | 0.107 | 2.24 | 1 | 0.385 | 0.030 |
| Ascorbate and aldarate metabolism | 6 | 2 | 0.110 | 2.21 | 1 | 0.385 | 0.500 |
| Pyrimidine metabolism | 41 | 6 | 0.112 | 2.19 | 1 | 0.385 | 0.226 |
| Sphingolipid metabolism | 18 | 2 | 0.137 | 1.98 | 1 | 0.385 | 0.036 |
| Phe metabolism | 10 | 3 | 0.147 | 1.92 | 1 | 0.385 | 0.692 |
| Glyoxylate and dicarboxylate metabolism | 16 | 4 | 0.158 | 1.85 | 1 | 0.385 | 0.417 |
| Propanoate metabolism | 18 | 6 | 0.159 | 1.84 | 1 | 0.385 | 0.267 |
| Arg and Pro metabolism | 37 | 9 | 0.162 | 1.82 | 1 | 0.385 | 0.344 |
| Butanoate metabolism | 21 | 2 | 0.170 | 1.77 | 1 | 0.385 | 0.000 |
| Val, Leu and Ile degradation | 35 | 2 | 0.175 | 1.75 | 1 | 0.385 | 0.000 |
| Amino sugar and nucleotide sugar metabolism | 34 | 6 | 0.175 | 1.74 | 1 | 0.385 | 0.003 |
| Val, Leu and Ile biosynthesis | 13 | 4 | 0.181 | 1.71 | 1 | 0.385 | 0.667 |
| Fatty acid biosynthesis | 38 | 2 | 0.200 | 1.61 | 1 | 0.385 | 0.000 |
| Citrate cycle (TCA cycle) | 20 | 5 | 0.201 | 1.60 | 1 | 0.385 | 0.147 |
| Purine metabolism | 64 | 8 | 0.204 | 1.59 | 1 | 0.385 | 0.189 |
| Fatty acid elongation in mitochondria | 27 | 1 | 0.205 | 1.59 | 1 | 0.385 | 0.000 |
| Fatty acid metabolism | 38 | 1 | 0.205 | 1.59 | 1 | 0.385 | 0.000 |
| Cys and Met metabolism | 25 | 3 | 0.209 | 1.56 | 1 | 0.385 | 0.092 |
| Nicotinate and nicotinamide metabolism | 9 | 1 | 0.217 | 1.53 | 1 | 0.385 | 0.000 |
| Aminoacyl‐tRNA biosynthesis | 67 | 13 | 0.231 | 1.47 | 1 | 0.388 | 0.138 |
| Gly, Ser and Thr metabolism | 25 | 5 | 0.234 | 1.45 | 1 | 0.388 | 0.571 |
| Galactose metabolism | 26 | 3 | 0.277 | 1.29 | 1 | 0.429 | 0.079 |
| Starch and sucrose metabolism | 17 | 6 | 0.285 | 1.26 | 1 | 0.429 | 0.244 |
| Tyr metabolism | 30 | 2 | 0.286 | 1.25 | 1 | 0.429 | 0.188 |
| Pentose phosphate pathway | 19 | 2 | 0.304 | 1.19 | 1 | 0.443 | 0.000 |
| Ala, Asp and Glu metabolism | 23 | 5 | 0.326 | 1.12 | 1 | 0.446 | 0.186 |
| Pantothenate and CoA biosynthesis | 12 | 4 | 0.330 | 1.11 | 1 | 0.446 | 0.000 |
| Lys degradation | 17 | 2 | 0.342 | 1.07 | 1 | 0.446 | 0.000 |
| Methane metabolism | 9 | 2 | 0.353 | 1.04 | 1 | 0.446 | 0.400 |
| Cyanoamino acid metabolism | 6 | 2 | 0.353 | 1.04 | 1 | 0.446 | 0.000 |
| Gln and Glu metabolism | 5 | 1 | 0.432 | 0.84 | 1 | 0.531 | 0.000 |
| Nitrogen metabolism | 7 | 2 | 0.468 | 0.76 | 1 | 0.560 | 0.000 |
| Glycolysis or Gluconeogenesis | 25 | 2 | 0.490 | 0.71 | 1 | 0.560 | 0.104 |
| Pyruvate metabolism | 24 | 2 | 0.490 | 0.71 | 1 | 0.560 | 0.000 |
| Porphyrin and chlorophyll metabolism | 23 | 1 | 0.551 | 0.60 | 1 | 0.615 | 0.000 |
| Phe, Tyr, and Trp biosynthesis | 4 | 2 | 0.588 | 0.53 | 1 | 0.642 | 1.000 |
| Ubiquinone and other terpenoid‐quinone biosynthesis | 3 | 1 | 0.646 | 0.44 | 1 | 0.689 | 0.000 |
| His metabolism | 7 | 1 | 0.754 | 0.28 | 1 | 0.787 | 1.000 |
| Biotin metabolism | 5 | 1 | 0.794 | 0.23 | 1 | 0.811 | 0.000 |
| Glycerolipid metabolism | 16 | 1 | 0.994 | 0.01 | 1 | 0.994 | 0.088 |